Inhibikase Therapeutics, Inc.IKTNASDAQ
LOADING
|||
Cash Flow Under Pressure
Below historical average, strong compound growth.
Left:
||||
Operating cash flow minus capital expenditures
Latest
$-19.15M
↓ 146% below average
Average (8y)
$-7.78M
Historical baseline
Range
High:$714987.00
Low:$-19.15M
CAGR
+124.6%
Consistent expansion
| Period | Value | Change |
|---|---|---|
| 2024 | $-19.15M | -5.8% |
| 2023 | $-18.10M | -2.9% |
| 2022 | $-17.59M | -23.1% |
| 2021 | $-14.30M | -1165.9% |
| 2020 | $-1.13M | -233.8% |
| 2019 | $-338290.00 | -147.3% |
| 2018 | $714987.00 | +665.7% |
| 2017 | $-126391.00 | -327.4% |
| 2016 | $-29573.00 | - |